2022
Community-based referral for tuberculosis preventive therapy is effective for treatment completion
Shenoi S, Kyriakides T, Dokubo E, Guddera V, Vranken P, Desai M, Friedland G, Moll A. Community-based referral for tuberculosis preventive therapy is effective for treatment completion. PLOS Global Public Health 2022, 2: e0001269. PMID: 36962910, PMCID: PMC10021376, DOI: 10.1371/journal.pgph.0001269.Peer-Reviewed Original ResearchTreatment completionCommunity-based identificationPreventive therapyIndependent predictorsGovernment primary care clinicsMedian age 35 yearsCommunity-based referralsHigher treatment completionMedian CD4 countTB preventive therapyTB endemic regionsTuberculosis preventive therapyComparison groupPrimary care clinicsClinic-based careAge 35 yearsCBR groupTeam of nursesSix-month courseMedian CD4Oral isoniazidCD4 countHIV careNight sweatsCare clinics
2017
Integrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts
Shenoi SV, Moll AP, Brooks RP, Kyriakides T, Andrews L, Kompala T, Upadhya D, Altice FL, Eksteen FJ, Friedland G. Integrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts. Open Forum Infectious Diseases 2017, 4: ofx092. PMID: 28695145, PMCID: PMC5499582, DOI: 10.1093/ofid/ofx092.Peer-Reviewed Original ResearchHuman immunodeficiency virusIntensive case findingCase findingResistant TBTB casesHIV testingRural South AfricaOverall case notification rateConcurrent HIV testingHIV coinfection rateHIV-negative tuberculosisMedian CD4 countCD4 cell countHIV/TBDrug-resistant TBCase notification ratesCase-finding strategyHIV-positive individualsHigh-risk populationTB symptom screeningPopulation-level ratesCD4 countTuberculosis symptomsSymptom screeningTB elimination
2016
Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study
Helou E, Shenoi S, Kyriakides T, Landry ML, Kozal M, Barakat LA. Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2016, 16: 261-266. PMID: 27903948, PMCID: PMC5423832, DOI: 10.1177/2325957416680028.Peer-Reviewed Original ResearchConceptsVirologic failureViral load levelsPill burdenAlcohol useHuman immunodeficiency virus (HIV) careLow-level HIV viremiaUndetectable viral load levelsAntiretroviral regimen changesAntiretroviral therapy changesExperienced virologic failureLow-level viremiaIntravenous drug useSubset of patientsFrequent clinic visitsPoor clinical outcomePossible risk factorsHepatitis C virusHIV viremiaMore comorbiditiesNonfailure groupVirologic suppressionVirological failureCD4 countConsecutive chartsClinic visits
2015
Trends in hospital deaths among human immunodeficiency virus–infected patients during the antiretroviral therapy era, 1995 to 2011
Cowell A, Shenoi SV, Kyriakides TC, Friedland G, Barakat LA. Trends in hospital deaths among human immunodeficiency virus–infected patients during the antiretroviral therapy era, 1995 to 2011. Journal Of Hospital Medicine 2015, 10: 608-614. PMID: 26130520, PMCID: PMC4560992, DOI: 10.1002/jhm.2409.Peer-Reviewed Original ResearchConceptsHospital deathAIDS deathsHuman immunodeficiency virus-infected patientsHigher CD4 cell countsAIDS infectionAntiretroviral therapy eraNon-AIDS deathsNon-AIDS malignanciesCD4 cell countHIV viral loadVirus-infected patientsHuman immunodeficiency virusUrban teaching hospitalTimes greater likelihoodCardiovascular comorbiditiesTherapy eraCD4 countInpatient mortalityImmunodeficiency syndromeLiver diseaseUnderlying liverViral loadImmunodeficiency virusMedical recordsAntiretroviral era
2011
Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial
Holodniy M, Brown ST, Cameron DW, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK, Anis A, Goodall R, Hudson F, Piaseczny M, Russo J, Schechter M, Deyton L, Darbyshire J, . Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. PLOS ONE 2011, 6: e14764. PMID: 21483491, PMCID: PMC3069000, DOI: 10.1371/journal.pone.0014764.Peer-Reviewed Original ResearchConceptsRe-treatment optionsART interruptionHIV infectionPrimary outcomeRetreatment optionsMultidrug resistanceAdvanced HIV diseaseAntiretroviral treatment interruptionARV treatment failurePrior AIDS diagnosisResistant HIV InfectionMedian CD4 countPrimary composite outcomeSerious adverse eventsMean viral loadBest medical managementOPTIMA trialCD4 countOpen labelTreatment interruptionAdverse eventsComposite outcomeFirst AIDSHIV diseaseAntiretroviral treatment
2001
Development and Application of a Genotypic AZT Resistance Assay
Kyriakides T, Heimer R. Development and Application of a Genotypic AZT Resistance Assay. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211-220. DOI: 10.1097/00126334-200111010-00002.Peer-Reviewed Original ResearchViral loadCD4 countAZT resistanceResistance indexResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentResistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityReaction assaysCountAssaysFurther supportIndexAntiretroviralsHIVDevelopment and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index.
Kyriakides TC, Heimer RR. Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211. PMID: 11694826, DOI: 10.1097/00042560-200111010-00002.Peer-Reviewed Original ResearchConceptsViral loadCD4 countResistance indexAZT resistanceResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentWild-type HIV-1Resistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityClinical samplesReaction assaysCountAssaysRelative predictive abilityFurther support